EligibleTrials

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

Recruiting · NCT02347111 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Illinois at Chicago

View the official record on ClinicalTrials.gov →
Atrial Fibrillation

Interventions studied

FlecainideSotalol

What this trial is about

In this pilot and feasibility study, the investigators will enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) in a cross-over study testing two different classes of anti arrhythmic drugs (AADs). This pilot and feasibility study will provide preliminary data for a larger study in which the investigators will test the hypothesis that a common AF genetic risk allele modulates response to different AADs.

Who can take part

Age range
18 Years to 100 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

4 locations listed across 1 US state.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.